Diagnostic efficacy of [18F]FDG PET/CT and [18F]FDG PET/MRI in preoperative staging of locoregional urinary bladder cancer: a systematic review and Meta-Analysis
Open Access
- 1 July 2025
- journal article
- review article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1241
Abstract
Background: This systematic review and meta-analysis aims to evaluate the diagnostic utility of [18F]Fluorodeoxyglucose ([18F]FDG) PET/CT and [18F]FDG PET/MRI in preoperative locoregional staging of bladder cancer (BC). Methods: A comprehensive search of PubMed and Scopus databases was conducted up to February 26, 2025, to collect and analyze diagnostic accuracy parameters. Statistical analyses, including publication bias assessment, interstudy heterogeneity evaluation, and effect size adjustment, were performed using Stata software, with a significance threshold set at p < 0.05. Results: A total of 25 eligible studies were identified. Among these, three studies utilized [18F]FDG PET/MRI for primary tumor detection, yielding a pooled sensitivity of 90%. In contrast, five studies employing [18F]FDG PET/CT for the same purpose reported a pooled sensitivity of 69%. Notably, [18F]FDG PET/MRI demonstrated threefold greater effectiveness in primary tumor detection compared to [18F]FDG PET/CT based on results of indirect comparison of true positive odds ratio between the two modalities. For lymph node staging, 18 studies employed [18F]FDG PET/CT, with pooled sensitivity and specificity estimates of 50% and 91%, respectively. Significant interstudy heterogeneity was observed in lymph node staging, primarily attributed to variations in PET/CT protocols. Studies incorporating bladder priming strategies, dual-time-point imaging, and contrast-enhanced CT protocols achieved superior sensitivity and specificity compared to traditional PET/CT approaches. Conclusion: The findings highlight the compelling potential of [18F]FDG PET/MRI for primary tumor staging in BC. Further research is warranted to explore this innovative modality’s role in locoregional BC evaluation. Additionally, substantial heterogeneity in [18F]FDG PET/CT protocols underscores the need for standardization to improve sensitivity. Thus, Future studies should focus on addressing these limitations by adopting optimized PET/CT protocols.Keywords
This publication has 50 references indexed in Scilit:
- Novel Therapies for High-Risk Non-Muscle Invasive Bladder CancerCurrent Oncology Reports, 2022
- Impact of 18 FDG- PET CT in the Management of Muscle Invasive Bladder CancerClinical Genitourinary Cancer, 2022
- Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC)Clinical Genitourinary Cancer, 2020
- PET/MRI in prostate cancer: a systematic review and meta-analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Integrated analysis of 18F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancerEuropean Radiology, 2019
- Pelvic Lymph Node Staging by Combined 18F-FDG-PET/CT Imaging in Bladder Cancer Prior to Radical CystectomyClinical Genitourinary Cancer, 2017
- The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysisWorld Journal of Urology, 2016
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0European Journal of Nuclear Medicine and Molecular Imaging, 2014
- Clinical value of FDG PET or PET/CT in urinary bladder cancer: A systemic review and meta-analysisEuropean Journal of Radiology, 2012
- FDG-PET for preoperative staging of bladder cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005